Gilead Sciences, Inc. (GILD) EBITDA Margin: 46.12%
Is Gilead Sciences, Inc.’s EBITDA margin high or low?
Gilead Sciences, Inc.'s EBITDA margin of 46.12% is 45% above its 5-year average of 31.82%, near the high end of its 5-year range (15.42%–46.12%).
The EBITDA margin for Gilead Sciences, Inc. (GILD) is 46.12% as of Tuesday, June 9, 2026. It is above its 12-month average by 49.89% (30.77%).
GILD EBITDA Margin Chart
GILD Average EBITDA Margin Chart
GILD Current vs Average EBITDA Margin Chart
GILD EBITDA Margin Metrics
EBITDA MARGIN
46.12%
EBITDA MARGIN AVG TTM
30.77%
EBITDA MARGIN AVG 3Y
33.17%
EBITDA MARGIN AVG 5Y
31.82%
EBITDA MARGIN AVG 10Y
42.48%
EBITDA MARGIN AVG 15Y
45.22%
EBITDA MARGIN AVG 20Y
47.44%
CURRENT VS TTM AVG
+49.89%
CURRENT VS 3Y AVG
+39.02%
CURRENT VS 5Y AVG
+44.93%
CURRENT VS 10Y AVG
+8.57%
CURRENT VS 15Y AVG
+1.98%
CURRENT VS 20Y AVG
-2.78%
GILD Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. (GILD) | — | 46.12% | 30.77% | 33.17% | 31.82% |
| Abbott Laboratories (ABT) | $158.94B | 26.06% | 25.95% | 26.39% | 26.63% |
| Intuitive Surgical, Inc. (ISRG) | $151.09B | 35.99% | 34.83% | 32.83% | 33.18% |
| Pfizer Inc. (PFE) | $146.48B | 24.12% | 26.30% | 27.39% | 29.84% |
| Danaher Corporation (DHR) | $133.37B | 28.27% | 29.38% | 31.44% | 31.51% |
| Thermo Fisher Scientific Inc. (TMO) | $183.61B | 25.73% | 26.63% | 26.49% | 27.97% |
| Amgen Inc. (AMGN) | $185.96B | 43.12% | 41.54% | 45.45% | 46.07% |
| CVS Health Corporation (CVS) | $123.84B | 2.45% | 3.06% | 3.76% | 4.57% |
| Bristol-Myers Squibb Company (BMY) | $115.34B | 30.18% | 18.37% | 30.35% | 29.39% |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.77B | 41.14% | 22.77% | 35.47% | 38.89% |
Margin Comparison
Gross Margin
78.8%
EBITDA Margin
46.1%
Operating Margin
39.7%
Net Margin
28.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
Gilead Sciences, Inc. EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Gilead Sciences, Inc. EBITDA Margin FAQ
- What is the EBITDA margin for Gilead Sciences, Inc. (GILD)?
- The EBITDA margin for GILD stock is 46.12%.
- Is Gilead Sciences, Inc.'s EBITDA margin high or low?
- Gilead Sciences, Inc.'s EBITDA margin of 46.12% is 45% above its 5-year average of 31.82%, near the high end of its 5-year range (15.42%–46.12%).
- What is the TTM average EBITDA margin for Gilead Sciences, Inc. (GILD)?
- The TTM average EBITDA margin for GILD stock is 30.77%.
- What is the 3Y average EBITDA margin for Gilead Sciences, Inc. (GILD)?
- The 3Y average EBITDA margin for GILD stock is 33.17%.
- What is the 5Y average EBITDA margin for Gilead Sciences, Inc. (GILD)?
- The 5Y average EBITDA margin for GILD stock is 31.82%.
- What is the 10Y average EBITDA margin for Gilead Sciences, Inc. (GILD)?
- The 10Y average EBITDA margin for GILD stock is 42.48%.
- What is the 15Y average EBITDA margin for Gilead Sciences, Inc. (GILD)?
- The 15Y average EBITDA margin for GILD stock is 45.22%.
- What is the 20Y average EBITDA margin for Gilead Sciences, Inc. (GILD)?
- The 20Y average EBITDA margin for GILD stock is 47.44%.
Gilead Sciences, Inc. EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | 46.12% |
| 2024-12-31 | 15.42% |
| 2023-12-31 | 38.71% |
| 2022-12-31 | 32.45% |
| 2021-12-31 | 41.49% |
| 2020-12-31 | 16.74% |
| 2019-12-31 | 33.67% |
| 2018-12-31 | 46.57% |
| 2017-12-31 | 61.03% |
| 2016-12-31 | 63.24% |
| 2015-12-31 | 71.83% |
| 2014-12-31 | 65.56% |
| 2013-12-31 | 43.39% |
| 2012-12-31 | 43.82% |
| 2011-12-31 | 49.59% |
| 2010-12-31 | 53.94% |
| 2009-12-31 | 53.98% |
| 2008-12-31 | 54.23% |
| 2007-12-31 | 52.38% |
| 2006-12-31 | 55.60% |
| 2005-12-31 | 56.44% |
| 2004-12-31 | 49.21% |
| 2003-12-31 | 40.42% |
| 2002-12-31 | 20.44% |
| 2001-12-31 | -45.34% |
| 2000-12-31 | -20.61% |
| 1999-12-31 | -23.14% |
| 1998-12-31 | -43.08% |
| 1997-12-31 | -43.01% |
| 1996-12-31 | -94.61% |
Related Metrics
About Gilead Sciences, Inc.
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Daniel O'Day